BIOMAT Database Logo BIOMAT Database Logo

Effects of M16209 on insulin secretion in isolated, perfused pancreases of normal and diabetic rats. 1995

K Nakayama, and N Murakami, and M Ohta, and K Kato, and T Notsu, and M Mizota, and I Miwa, and J Okuda
Department of Pharmacology, Fuji Central Research Laboratory, Mochida Pharmaceutical Co., Ltd., Tokyo, Japan.

We investigated the stimulatory effect of M16209 (1-(3-bromobenzo[b]furan-2-yl-sulfonyl)hydantoin), a novel aldose reductase inhibitor, on insulin secretion using isolated, perfused pancreases of rats. In the pancreases from normal rats, M16209 (100 microM) greatly augmented glucose-stimulated insulin secretion, but showed no effect on unstimulated insulin secretion at 2.8 mM glucose. In contrast, gliclazide (10 microM), a sulfonylurea, strongly enhanced both glucose-stimulated and unstimulated insulin secretion. Sorbinil and epalrestat, potent aldose reductase inhibitors, had no stimulatory effect on insulin secretion. M16209 (100 microM) improved appreciably the decreased insulin response to 22.2 mM glucose and enhanced slightly unstimulated insulin secretion in the pancreases of rats with neonatally streptozotocin-induced, non-insulin-dependent diabetes mellitus (NIDDM). Gliclazide (10 microM), however, failed to affect the pancreases of NIDDM rats. Furthermore, M16209 showed no appreciable effect on ATP-sensitive K(+)-channels in pancreatic beta-cells. These results suggest that M16209, unlike sulfonylureas, selectively enhances glucose-stimulated insulin secretion in both normal and NIDDM rats through a direct action on the pancreas. The site of action remains unknown, but the inhibition of aldose reductase or the ATP-sensitive K+ channels is unlikely to be involved.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D010179 Pancreas A nodular organ in the ABDOMEN that contains a mixture of ENDOCRINE GLANDS and EXOCRINE GLANDS. The small endocrine portion consists of the ISLETS OF LANGERHANS secreting a number of hormones into the blood stream. The large exocrine portion (EXOCRINE PANCREAS) is a compound acinar gland that secretes several digestive enzymes into the pancreatic ductal system that empties into the DUODENUM.
D010477 Perfusion Treatment process involving the injection of fluid into an organ or tissue. Perfusions
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D006827 Hydantoins Compounds based on imidazolidine dione. Some derivatives are ANTICONVULSANTS. Hydantoin,Imidazolidine-2,4-Diones,Imidazolidine 2,4 Diones
D000078790 Insulin Secretion Production and release of insulin from PANCREATIC BETA CELLS that primarily occurs in response to elevated BLOOD GLUCOSE levels. Secretion, Insulin
D000449 Aldehyde Reductase An enzyme that catalyzes reversibly the oxidation of an aldose to an alditol. It possesses broad specificity for many aldoses. EC 1.1.1.21. Aldose Reductase,Aldose Reductase Ia,Aldose Reductase Ib,Erythrose Reductase,Xylose Reductase,Reductase Ia, Aldose,Reductase Ib, Aldose,Reductase, Aldehyde,Reductase, Aldose,Reductase, Erythrose,Reductase, Xylose

Related Publications

K Nakayama, and N Murakami, and M Ohta, and K Kato, and T Notsu, and M Mizota, and I Miwa, and J Okuda
Impaired insulin secretion in perfused pancreases isolated from offspring of female rats fed a low protein whey-based diet.
July 2008, JOP : Journal of the pancreas,
K Nakayama, and N Murakami, and M Ohta, and K Kato, and T Notsu, and M Mizota, and I Miwa, and J Okuda
Altered insulin and glucagon secretion in perfused ethionine-treated rat pancreases.
December 1982, The American journal of physiology,
K Nakayama, and N Murakami, and M Ohta, and K Kato, and T Notsu, and M Mizota, and I Miwa, and J Okuda
Defective insulin and glucagon secretion in isolated perfused pancreata of diabetic WBN/Kob rats.
January 1995, Pancreas,
K Nakayama, and N Murakami, and M Ohta, and K Kato, and T Notsu, and M Mizota, and I Miwa, and J Okuda
Loss of a priming effect of glucose on A and D cell secretion in perfused pancreases from alloxan-diabetic rats: role of insulin and alloxan.
January 1983, Diabetologia,
K Nakayama, and N Murakami, and M Ohta, and K Kato, and T Notsu, and M Mizota, and I Miwa, and J Okuda
Insulin effects on pantothenic acid uptake in isolated perfused working hearts from diabetic rats.
October 1988, Diabetes,
K Nakayama, and N Murakami, and M Ohta, and K Kato, and T Notsu, and M Mizota, and I Miwa, and J Okuda
Consequences of ventromedial hypothalamic lesions upon insulin and glucagon secretion by subsequently isolated perfused pancreases in the rat.
April 1980, The Journal of clinical investigation,
K Nakayama, and N Murakami, and M Ohta, and K Kato, and T Notsu, and M Mizota, and I Miwa, and J Okuda
Direct neural effect of lateral hypothalamic stimulation on insulin secretion by pancreases of normal and obese rats.
March 1990, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
K Nakayama, and N Murakami, and M Ohta, and K Kato, and T Notsu, and M Mizota, and I Miwa, and J Okuda
[The effect of insulin on the metabolism of isolated perfused livers of normal and alloxan-diabetic rats. I. The metabolism of isolated perfused livers in normal and alloxan-diabetic rats under various experimental conditions].
June 1966, Diabetologia,
K Nakayama, and N Murakami, and M Ohta, and K Kato, and T Notsu, and M Mizota, and I Miwa, and J Okuda
Increased somatostatin release from pancreases of alloxan diabetic rats perfused in vitro.
February 1979, Life sciences,
K Nakayama, and N Murakami, and M Ohta, and K Kato, and T Notsu, and M Mizota, and I Miwa, and J Okuda
Studies of the metabolism of isolated livers of normal and alloxan-diabetic rats perfused with insulin.
May 1968, Diabetes,
Copied contents to your clipboard!